Financial Overview - Arovella Therapeutics Limited (ASX:ALA) has a market capitalization of $136.7 million[16] - The company has 1,188.6 million shares on issue[16] - Arovella's cash balance as of June 30, 2025, was $20.9 million[16, 20] - Biotech Capital Management Pty Ltd holds 108,526,184 shares, representing 9.17% ownership[16] ALA-101 Clinical Development - ALA-101, a potential treatment for CD19-positive blood cancers, is progressing to phase 1 clinical trials, expected to commence in early 2026[8, 96] - The company completed a $15 million placement to fully fund enrollment and report initial safety and efficacy data for the phase 1 trial for ALA-101[21] - Arovella is conducting IND-enabling non-clinical safety and efficacy studies to support regulatory approval for ALA-101[64] Cell Therapy Market and Technology - The cell therapy market is expected to reach $61.2 billion by 2030[25] - 40-60% of patients relapse post-CAR-T therapy[25] - Recent cell therapy acquisition deals for in vivo CAR therapies in Phase 1 reached up to $2,100 million[18]